JP2018510894A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510894A5
JP2018510894A5 JP2017552890A JP2017552890A JP2018510894A5 JP 2018510894 A5 JP2018510894 A5 JP 2018510894A5 JP 2017552890 A JP2017552890 A JP 2017552890A JP 2017552890 A JP2017552890 A JP 2017552890A JP 2018510894 A5 JP2018510894 A5 JP 2018510894A5
Authority
JP
Japan
Prior art keywords
dose
administration
pharmaceutical composition
days
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017552890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510894A (ja
JP6728221B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/024841 external-priority patent/WO2016164218A1/en
Publication of JP2018510894A publication Critical patent/JP2018510894A/ja
Publication of JP2018510894A5 publication Critical patent/JP2018510894A5/ja
Application granted granted Critical
Publication of JP6728221B2 publication Critical patent/JP6728221B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017552890A 2015-04-07 2016-03-30 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン Active JP6728221B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
US62/144,054 2015-04-07
US201562162596P 2015-05-15 2015-05-15
US62/162,596 2015-05-15
PCT/US2016/024841 WO2016164218A1 (en) 2015-04-07 2016-03-30 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019231631A Division JP7228503B2 (ja) 2015-04-07 2019-12-23 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン

Publications (3)

Publication Number Publication Date
JP2018510894A JP2018510894A (ja) 2018-04-19
JP2018510894A5 true JP2018510894A5 (https=) 2019-05-09
JP6728221B2 JP6728221B2 (ja) 2020-07-22

Family

ID=57072843

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017552890A Active JP6728221B2 (ja) 2015-04-07 2016-03-30 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
JP2019231631A Active JP7228503B2 (ja) 2015-04-07 2019-12-23 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
JP2021086909A Active JP7422277B2 (ja) 2015-04-07 2021-05-24 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019231631A Active JP7228503B2 (ja) 2015-04-07 2019-12-23 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
JP2021086909A Active JP7422277B2 (ja) 2015-04-07 2021-05-24 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン

Country Status (27)

Country Link
US (1) US10143693B2 (https=)
EP (3) EP3744326B1 (https=)
JP (3) JP6728221B2 (https=)
KR (3) KR102606678B1 (https=)
AU (4) AU2016244801B2 (https=)
BR (1) BR112017021383A2 (https=)
CA (2) CA2925908C (https=)
CY (1) CY1123203T1 (https=)
DK (2) DK3744326T3 (https=)
EA (1) EA037185B1 (https=)
ES (2) ES2802299T3 (https=)
FI (1) FI3744326T3 (https=)
HR (2) HRP20201027T1 (https=)
HU (2) HUE065435T2 (https=)
IL (3) IL309340B1 (https=)
LT (2) LT3744326T (https=)
MA (1) MA41917B1 (https=)
MD (2) MD3744326T2 (https=)
NZ (1) NZ735952A (https=)
PL (2) PL3744326T3 (https=)
PT (2) PT3280416T (https=)
RS (2) RS65024B1 (https=)
SI (2) SI3280416T1 (https=)
SM (2) SMT202300478T1 (https=)
TW (1) TWI694825B (https=)
UA (1) UA118732C2 (https=)
WO (1) WO2016164218A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016244801B2 (en) 2015-04-07 2020-06-25 Janssen Pharmaceutica Nv Dosing regimen for missed doses for long-acting injectable paliperidone esters
ES3036965T3 (en) * 2017-10-27 2025-09-25 Geneora Pharma Shijiazhuang Co Ltd Dosage regimen of paliperidone palmitate extended-release injectable suspension
IL303254A (en) 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
MX2023006368A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
IL303253A (en) * 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Dosing regimens associated with delayed-release injectable formulations of paliperidone
PL4025187T3 (pl) 2020-11-30 2024-04-29 Janssen Pharmaceutica Nv Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu
WO2023021008A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
IL311134A (en) * 2021-08-30 2024-04-01 Janssen Pharmaceutica Nv Dosing regimens associated with delayed-release paliperidone injection formulations
KR102869809B1 (ko) 2023-11-21 2025-10-13 주식회사 엘지에너지솔루션 양극 및 이를 포함하는 전고체 전지

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
BRPI0821408A2 (pt) * 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
EP2485712A1 (en) * 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
MX2012005083A (es) * 2009-10-30 2012-09-28 Janssen Pharmaceutica Nv Regimen de dosificacion asociado con esteres de paliperidona inyetables de accion prolongada.
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
AU2016244801B2 (en) 2015-04-07 2020-06-25 Janssen Pharmaceutica Nv Dosing regimen for missed doses for long-acting injectable paliperidone esters

Similar Documents

Publication Publication Date Title
JP2018510894A5 (https=)
JP2013509435A5 (https=)
JP2017513809A5 (https=)
JP2015187125A5 (https=)
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
RU2008138381A (ru) Режимы дозирования адреналина
NZ599558A (en) Dosing regimen associated with long-acting injectable paliperidone esters
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
JP2015520196A5 (https=)
JP2016514132A5 (https=)
HRP20161533T1 (hr) Supstance koje sadrže buprenorfin
JP2017533972A5 (https=)
RU2016149316A (ru) Лечение ревматоидного артрита
JP2019511506A5 (https=)
FI3733712T3 (fi) Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä
JP2016515137A5 (https=)
RU2017145643A (ru) Фармацевтические композиции для пролонгированного высвобождения себакоил-диналбуфинового эфира
JP2009539916A5 (https=)
RU2008151727A (ru) Комбинация аналогов соматостатина с антагонистом рецептора дофамина или рецептора гормона роста
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
JP2014508174A5 (https=)
BR112022003687A2 (pt) Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina
SI2686002T1 (en) A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas